E-LIB Suche - Ergebnisse für: Zwierenga, F.

1

41P The influence of ROS1 fusion partners and resistance me..:

Zwierenga, F. ; Dijkhuizen, C. ; Korthuis, P....
ESMO Open. 9 (2024) - p. 102620 , 2024

2

A brief report on combination chemotherapy and anti–program..:

Mankor, Joanne ; Zwierenga, F ; Dumoulin, Daphne..
Mankor , J , Zwierenga , F , Dumoulin , D , Neefjes , JJC & Aerts , J 2020 , ' A brief report on combination chemotherapy and anti–programmed death (ligand) 1 treatment in small-cell lung cancer: Did we choose the optimal chemotherapy backbone? ' , European Journal of Cancer , vol. 137 , pp. 40-44 . https://doi.org/10.1016/j.ejca.2020.06.029. , 2020

Link: https://pure.eur.nl/en/p..

3

A brief report on combination chemotherapy and anti–program..:

Mankor, J.M. (Joanne M.) ; Zwierenga, F. (Fenneke) ; Dumoulin, D.W. (Daphne W.)..
http://repub.eur.nl/pub/129345. , 2020

Link: http://repub.eur.nl/pub/..

4

A comprehensive overview of the heterogeneity of EGFR exon ..:

Zwierenga, Fenneke ; van Veggel, Bianca A.M.H. ; van den Berg, Anke...
Cancer Treatment Reviews. 120 (2023) - p. 102628 , 2023

Link: https://doi.org/10.1016/..

5

A comprehensive overview of the heterogeneity of EGFR exon ..:

Zwierenga, Fenneke ; van Veggel, Bianca A M H ; van den Berg, Anke...
https://research.rug.nl/en/publications/f4e68b03-bdcc-4637-b446-dcbd77f04d2a. , 2023

Link: https://hdl.handle.net/1..